Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year
Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.0 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).
This is the third installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, expected by the end of this year.
Under the terms of the amended Subscription Agreement, Atlas has waived the market capitalization and liquidity conditions for up to EUR 3.5 million in mandatorily convertible bonds to be issued before the topline data is received by the end of 2023.
Under the Funding Program, Atlas has committed to up to EUR 20 million in funding over a 24-month period, of which it has now subscribed to EUR 11.5 million, leaving a remainder of EUR 8.5 million.
Tom Graney, CEO of Oxurion, said: “We are very focused right now on reaching the key catalyst of reporting the topline data from the KALAHARI trial this year. With the sustained support from Atlas, we expect to achieve that milestone without the need for additional capital. The KALAHARI trial is evaluating Oxurion’s THR-149 versus market leader aflibercept, and Oxurion hopes to demonstrate the superior efficacy of THR-149 in treating the up to 50% of patients with diabetic macular edema (DME) for whom the current standard of care is suboptimal. DME is a large unmet need, because it remains the leading cause of blindness for working-aged people; we believe that THR-149 holds the promise of providing a much-needed alternative for the millions of patients worldwide for whom the current standard of care is suboptimal. We look forward to sharing the KALAHARI topline results this year.”
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Chief Executive Officer
Tel: +32 16 75 13 10
Chief Business Officer
Tel: +32 16 75 13 10
Mary T. Conway
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Opjustering af forventninger 2023 og resultatforventninger 20247.12.2023 16:47:03 CET | pressemeddelelse
Nordfyns Bank koncernen opjusterer forventningerne for hele 2023 til et resultat før skat i niveauet 120 - 140 mio. kr. fra tidligere udmeldte forventninger om et resultat før skat i niveauet 95 - 115 mio. kr. Opjusteringen sker som følge af højere kursreguleringer samt et lavere nedskrivningsbehov. Samtidigt meddeles det, at Nordfyns Bank koncernen forventer for 2024 at opnå et resultat før skat, som vil ligge i niveauet 70 - 100 mio. kr. Forventningerne er forbundet med usikkerhed og afhænger blandt andet af den fremtidige samfundsmæssige økonomiske udvikling, herunder udviklingen i det generelle renteniveau, kursreguleringer som følge af udviklingen på de finansielle markeder, samt udviklingen i nedskrivningsbehovet. Venlig hilsen Nordfyns Bank Vedhæftet fil Meddelelse_nr12_2023
Eimskip: Transaction by a person closely associated with a PDMR7.12.2023 16:44:43 CET | Press release
Please find attached notifications regarding transactions by a person closely associated with a PDMR of Eimskipafélag Íslands hf., cf. Art. 19 of MAR regulation. Further information can be found in the attached notifications. Attachments Sjávarlind til Kauphallar 1Sjávarlind til Kauphallar 2
Finanskalender 20247.12.2023 16:10:04 CET | pressemeddelelse
Bestyrelsen har vedtaget følgende terminer for offentliggørelse af regnskabsmeddelelser og afholdelse af ordinær generalforsamling: Årsregnskab 202314. marts 2024Periodemeddelelse17. april 2024Generalforsamling17. april 2024Periodemeddelelse22. august 2024Periodemeddelelse24. oktober 2024 Bemærk venligst, at seneste frist for fremsættelse af krav om optagelse af et bestemt emne på dagsordenen, er seks uger før afholdelsen af årets generalforsamling (§ 7.2 i selskabets vedtægter). Emner, der ønskes optaget på årets generalforsamling, skal således være selskabet skriftligt i hænde senest onsdag den 5. marts 2024. Med venlig hilsen Torben Schultz Administrerende direktør For yderligere oplysninger venligst kontakt Adm. direktør Torben Schultz, 40 10 28 76 Vedhæftet fil Meddelelse nr 10 i 2023 (finanskalender 2024)
Update on re-sale of unsecured bonds held in treasury and share buyback7.12.2023 15:37:23 CET | Press release
Golar LNG Limited (“Golar” or the “Company”) announces that it has recently re-sold $30.5 million notional value of its senior unsecured bonds maturing 20 October 2025 (ISIN NO0011123432) which were previously held in treasury. Following the sale, Golar maintains $130.6 million notional value of unsecured bonds in treasury. The Company also provides an update on its previously announced share buyback program with total approved amount of up to $150.0 million. Since 30 September 2023, the company has bought back a total of 1,126,682 shares. Upon cancellation of these shares, the total number of outstanding shares will be reduced to 104,798,000. Of the $150.0 million approved share buyback scheme, $92.9 million remains available for further repurchases which will continue to be opportunistically pursued. Golar LNG Limited Hamilton, Bermuda December 7, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Directorate change7.12.2023 15:17:27 CET | Press release
Volta Finance Limited (VTA/VTAS) Directorate Change NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 December 2023 Retirement of director The Board announces that Mr Graham Harrison, a non-executive director and Chair of the Management Engagement Committee of the Company, has retired from the Board with effect from 6 December 2023. Mr Harrison has been on the Board since October 2015, and the Directors would like to express their gratitude for his valuable contribution during his tenure. Upon the retirement of Mr Harrison, the Board has approved the appointment of Mrs Joanne Peacegood, a non-executive director, to the role of Chair of the Management Engagement Committee. CONTACTS Company Secretary and Administrator BNP Paribas S.A, Guernsey Branch firstname.lastname@example.org +44 (0) 1481 750 853 Corporate Broker Cavendish Securities plc Andrew Worne Daniel Balabanoff +44 (0) 20 7397 8900 ***** ABOUT VOLTA FINANCE L